Trial Profile
A Phase II Trial of Afatinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of Esophagus
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Feb 2021
Price :
$35
*
At a glance
- Drugs Afatinib (Primary)
- Indications Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 04 Aug 2020 Status changed from active, no longer recruiting to completed.
- 04 Aug 2020 Results assessing clinical activity of, safety of, and predictive biomarkers for afatinib in patients with recurrent/metastatic esophageal squamous cell carcinoma, published in the Cancer.
- 07 Feb 2019 Planned End Date changed from 1 Jan 2019 to 1 Jan 2020.